Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Anil Kumar Chandraker, M.B.,Ch.B.

TitleAssociate Professor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham and Women's Hospital
Mrb-404b
75 Francis St
Boston MA 02115
Phone617/732-7412
Fax617/264-5108

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Daly KP, Seifert ME, Chandraker A, Zurakowski D, Nohria A, Givertz MM, Karumanchi SA, Briscoe DM. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2013 Jan; 32(1):120-8.
    View in: PubMed
  2. Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant. 2012 Oct; 12(10):2575-87.
    View in: PubMed
  3. Riella LV, Chandraker A. Stem cell therapy in kidney transplantation. JAMA. 2012 Jul 11; 308(2):130; author reply 130-1.
    View in: PubMed
  4. Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant. 2012 Aug; 12(8):1975-82.
    View in: PubMed
  5. De Serres SA, Mfarrej BG, Grafals M, Riella LV, Magee CN, Yeung MY, Dyer C, Ahmad U, Chandraker A, Najafian N. Derivation and validation of a cytokine-based assay to screen for acute rejection in renal transplant recipients. Clin J Am Soc Nephrol. 2012 Jun; 7(6):1018-25.
    View in: PubMed
  6. Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant. 2012 May-Jun; 26(3):E184-90.
    View in: PubMed
  7. Lee BT, Kumar V, Williams TA, Abdi R, Bernhardy A, Dyer C, Conte S, Genovese G, Ross MD, Friedman DJ, Gaston R, Milford E, Pollak MR, Chandraker A. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant. 2012 Jul; 12(7):1924-8.
    View in: PubMed
  8. Riella LV, Liu T, Yang J, Chock S, Shimizu T, Mfarrej B, Batal I, Xiao X, Sayegh MH, Chandraker A. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant. 2012 Apr; 12(4):846-55.
    View in: PubMed
  9. Sheashaa HA, Rennke HG, Bakr MA, Abbas TM, Atta AF, Sangak A, Mah H, Milford E, Chandraker A. Impact of accidental discovery of renal cell carcinoma at time of renal transplantation on patient or graft survival. Transplantation. 2011 Nov 27; 92(10):1123-8.
    View in: PubMed
  10. Riella LV, Ueno T, Batal I, De Serres SA, Bassil R, Elyaman W, Yagita H, Medina-Pestana JO, Chandraker A, Najafian N. Blockade of Notch ligand d1 promotes allograft survival by inhibiting alloreactive Th1 cells and cytotoxic T cell generation. J Immunol. 2011 Nov 1; 187(9):4629-38.
    View in: PubMed
  11. Gabardi S, Catella J, Martin ST, Perrone R, Chandraker A, Magee CC, McDevitt-Potter LM. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients. Ann Pharmacother. 2011 Sep; 45(9):e48.
    View in: PubMed
  12. Yang J, Riella LV, Chock S, Liu T, Zhao X, Yuan X, Paterson AM, Watanabe T, Vanguri V, Yagita H, Azuma M, Blazar BR, Freeman GJ, Rodig SJ, Sharpe AH, Chandraker A, Sayegh MH. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol. 2011 Aug 1; 187(3):1113-9.
    View in: PubMed
  13. Paterson AM, Brown KE, Keir ME, Vanguri VK, Riella LV, Chandraker A, Sayegh MH, Blazar BR, Freeman GJ, Sharpe AH. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011 Aug 1; 187(3):1097-105.
    View in: PubMed
  14. Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal. Pharmacotherapy. 2011 Jun; 31(6):566-73.
    View in: PubMed
  15. Tsaur I, Karalis A, Blaheta R, Juengel E, Vallo S, Scheuermann EH, Kachel HG, Waaga-Gasser AM, Chandraker A, Obermüller N, Probst M. Transitional cell carcinoma of the native urinary tract after kidney transplantation: recommendations following a long-term retrospective analysis. Am J Med Sci. 2011 Jun; 341(6):478-83.
    View in: PubMed
  16. De Serres SA, Vadivel N, Mfarrej BG, Grafals M, DeJoseph M, Dyer C, Magee CN, Chandraker A, Gallon LG, Najafian N. Monocyte-secreted inflammatory cytokines are associated with transplant glomerulopathy in renal allograft recipients. Transplantation. 2011 Mar 15; 91(5):552-9.
    View in: PubMed
  17. Riella LV, Watanabe T, Sage PT, Yang J, Yeung M, Azzi J, Vanguri V, Chandraker A, Sharpe AH, Sayegh MH, Najafian N. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant. 2011 Apr; 11(4):832-40.
    View in: PubMed
  18. Lin J, McGovern ME, Brunelli SM, Gaccione P, Malek S, Tullius SG, Chandraker AK, Milford EL. Longitudinal trends and influence of BMI mismatch in living kidney donors and their recipients. Int Urol Nephrol. 2011 Sep; 43(3):891-7.
    View in: PubMed
  19. Riella LV, Rennke HG, Grafals M, Chandraker A. Hypophosphatemia in kidney transplant recipients: report of acute phosphate nephropathy as a complication of therapy. Am J Kidney Dis. 2011 Apr; 57(4):641-5.
    View in: PubMed
  20. Tsaur I, Gasser M, Aviles B, Lutz J, Lutz L, Grimm M, Lange V, Lopau K, Heemann U, Germer CT, Chandraker A, Waaga-Gasser AM. Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients. Kidney Int. 2011 May; 79(9):1005-12.
    View in: PubMed
  21. Bedi DS, Riella LV, Tullius SG, Chandraker A. Animal models of chronic allograft injury: contributions and limitations to understanding the mechanism of long-term graft dysfunction. Transplantation. 2010 Nov 15; 90(9):935-44.
    View in: PubMed
  22. Lin J, Kramer H, Chandraker AK. Mortality among living kidney donors and comparison populations. N Engl J Med. 2010 Aug 19; 363(8):797-8.
    View in: PubMed
  23. Gabardi S, Waikar SS, Martin S, Roberts K, Chen J, Borgi L, Sheashaa H, Dyer C, Malek SK, Tullius SG, Vadivel N, Grafals M, Abdi R, Najafian N, Milford E, Chandraker A. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol. 2010 Jul; 5(7):1298-304.
    View in: PubMed
  24. Vadivel N, Surana SP, Galvez-Trevino R, Chandraker AK. Quiz page May 2010: debilitating pain of the hands and feet following kidney transplant. Am J Kidney Dis. 2010 May; 55(5):A33-5.
    View in: PubMed
  25. Erickson AL, Roberts K, Malek SK, Chandraker AK, Tullius SG, Gabardi S. Analysis of infusion-site reactions in renal transplant recipients receiving peripherally administered rabbit antithymocyte globulin as compared with basiliximab. Transpl Int. 2010 Jun; 23(6):636-40.
    View in: PubMed
  26. Yang J, Riella LV, Boenisch O, Popoola J, Robles S, Watanabe T, Vanguri V, Yuan X, Guleria I, Turka LA, Sayegh MH, Chandraker A. Paradoxical functions of B7: CD28 costimulation in a MHC class II-mismatched cardiac transplant model. Am J Transplant. 2009 Dec; 9(12):2837-44.
    View in: PubMed
  27. Waaga-Gasser AM, Grimm MR, Lutz J, Lange V, Lenhard SM, Aviles B, Kist-van Holthe JE, Lebedeva T, Samsonov D, Meyer D, Hancock WW, Heemann U, Gasser M, Chandraker A. Regulatory allospecific T cell clones abrogate chronic allograft rejection. J Am Soc Nephrol. 2009 Apr; 20(4):820-30.
    View in: PubMed
  28. Grafals M, Chandraker A. New approaches for desensitization strategies prior to kidney transplantation. Am J Kidney Dis. 2009 Mar; 53(3):370-2.
    View in: PubMed
  29. Boenisch O, Chandraker A. Predictive biomarkers of renal allograft failure. Expert Opin Med Diagn. 2008 Nov; 2(11):1279-90.
    View in: PubMed
  30. Pomahac B, Aflaki P, Chandraker A, Pribaz JJ. Facial transplantation and immunosuppressed patients: a new frontier in reconstructive surgery. Transplantation. 2008 Jun 27; 85(12):1693-7.
    View in: PubMed
  31. Chandraker A, Mannon RB. Care of the kidney transplant recipient. Clin J Am Soc Nephrol. 2008 Mar; 3 Suppl 2:S27-8.
    View in: PubMed
  32. Winkelmayer WC, Chandraker A. Pottransplantation anemia: management and rationale. Clin J Am Soc Nephrol. 2008 Mar; 3 Suppl 2:S49-55.
    View in: PubMed
  33. Yang J, Popoola J, Khandwala S, Vadivel N, Vanguri V, Yuan X, Dada S, Guleria I, Tian C, Ansari MJ, Shin T, Yagita H, Azuma M, Sayegh MH, Chandraker A. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation. 2008 Feb 5; 117(5):660-9.
    View in: PubMed
  34. Huurman VA, Unger WW, Koeleman BP, Oaks MK, Chandraker AK, Terpstra OT, Roep BO. Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y. Clin Exp Immunol. 2007 Dec; 150(3):487-93.
    View in: PubMed
  35. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007 Aug; 13(8):952-61.
    View in: PubMed
  36. Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl Int. 2007 Dec; 20(12):993-1015.
    View in: PubMed
  37. Vadivel N, Tullius SG, Chandraker A. Chronic allograft nephropathy. Semin Nephrol. 2007 Jul; 27(4):414-29.
    View in: PubMed
  38. Vadivel N, Trikudanathan S, Chandraker A. Transplant tolerance through costimulation blockade--are we there yet? Front Biosci. 2007; 12:2935-46.
    View in: PubMed
  39. Winkelmayer WC, Mehta J, Chandraker A, Owen WF, Avorn J. Predialysis nephrologist care and access to kidney transplantation in the United States. Am J Transplant. 2007 Apr; 7(4):872-9.
    View in: PubMed
  40. Winkelmayer WC, Schaeffner ES, Chandraker A, Kramar R, Rumpold H, Sunder-Plassmann G, Födinger M. A J-shaped association between high-sensitivity C-reactive protein and mortality in kidney transplant recipients. Transpl Int. 2007 Jun; 20(6):505-11.
    View in: PubMed
  41. Ali SH, Chandraker A, DeCaprio JA. Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther. 2007; 12(1):1-6.
    View in: PubMed
  42. Winkelmayer WC, Chandraker A, Alan Brookhart M, Kramar R, Sunder-Plassmann G. A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant. 2006 Dec; 21(12):3559-66.
    View in: PubMed
  43. Pendse SS, Vadivel N, Ramos E, Mudge GH, Von Visger T, Fang JC, Chandraker A. BK viral reactivation in cardiac transplant patients: evidence for a double-hit hypothesis. J Heart Lung Transplant. 2006 Jul; 25(7):814-9.
    View in: PubMed
  44. Josephson MA, Williams JW, Chandraker A, Randhawa PS. Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl Infect Dis. 2006 Jun; 8(2):95-101.
    View in: PubMed
  45. Martins PN, Chandraker A, Tullius SG. Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment. Transpl Int. 2006 May; 19(5):351-9.
    View in: PubMed
  46. Tinckam KJ, Chandraker A. Mechanisms and role of HLA and non-HLA alloantibodies. Clin J Am Soc Nephrol. 2006 May; 1(3):404-14.
    View in: PubMed
  47. Chandraker A, Tullius SG. Induction therapy: are we picking our battles? Clin J Am Soc Nephrol. 2006 May; 1(3):356-7.
    View in: PubMed
  48. Sayegh MH, Chandraker A. Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin? Nat Clin Pract Nephrol. 2006 Mar; 2(3):134-5.
    View in: PubMed
  49. Ansari MJ, Tinckam K, Chandraker A. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005 May 12; 352(19):2027-8; author reply 2027-8.
    View in: PubMed
  50. Chandraker A, Huurman V, Hallett K, Yuan X, Tector AJ, Park CH, Lu E, Zavazava N, Oaks M. CTLA-4 is important in maintaining long-term survival of cardiac allografts. Transplantation. 2005 Apr 27; 79(8):897-903.
    View in: PubMed
  51. Winkelmayer WC, Kramar R, Curhan GC, Chandraker A, Endler G, Födinger M, Hörl WH, Sunder-Plassmann G. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol. 2005 Jan; 16(1):255-60.
    View in: PubMed
  52. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy. 2004 Oct; 24(10):1323-30.
    View in: PubMed
  53. Imitola J, Comabella M, Chandraker AK, Dangond F, Sayegh MH, Snyder EY, Khoury SJ. Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. Am J Pathol. 2004 May; 164(5):1615-25.
    View in: PubMed
  54. Winkelmayer WC, Kewalramani R, Rutstein M, Gabardi S, Vonvisger T, Chandraker A. Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol. 2004 May; 15(5):1347-52.
    View in: PubMed
  55. Izawa A, Sayegh MH, Chandraker A. The antagonism of calcineurin inhibitors and costimulatory blockers: fact or fiction? Transplant Proc. 2004 Mar; 36(2 Suppl):570S-573S.
    View in: PubMed
  56. Gasser M, Waaga-Gasser AM, Kist-van Holthe JE, Yuan X, Lenhard SM, Abdallah KA, Chandraker A. Chronic rejection: insights from a novel immunosuppressive-free model of kidney transplantation. J Am Soc Nephrol. 2004 Mar; 15(3):687-94.
    View in: PubMed
  57. Goggins WC, Pascual MA, Powelson JA, Magee C, Tolkoff-Rubin N, Farrell ML, Ko DS, Williams WW, Chandraker A, Delmonico FL, Auchincloss H, Cosimi AB. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation. 2003 Sep 15; 76(5):798-802.
    View in: PubMed
  58. Salama AD, Yuan X, Nayer A, Chandraker A, Inobe M, Uede T, Sayegh MH. Interaction between ICOS-B7RP1 and B7-CD28 costimulatory pathways in alloimmune responses in vivo. Am J Transplant. 2003 Apr; 3(4):390-5.
    View in: PubMed
  59. Yuan X, Salama AD, Dong V, Schmitt I, Najafian N, Chandraker A, Akiba H, Yagita H, Sayegh MH. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol. 2003 Mar 15; 170(6):2949-55.
    View in: PubMed
  60. Kist-van Holthe JE, Gasser M, Womer K, Najafian N, Dong V, Samsonov DV, Geehan CS, Chandraker A, Sayegh MH, Waaga AM. Regulatory functions of alloreactive Th2 clones in human renal transplant recipients. Kidney Int. 2002 Aug; 62(2):627-31.
    View in: PubMed
  61. Yuan X, Dong VM, Coito AJ, Waaga AM, Salama AD, Benjamin CD, Sayegh MH, Chandraker A. A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection. Transplantation. 2002 Jun 15; 73(11):1736-42.
    View in: PubMed
  62. Dong VM, Yuan X, Coito AJ, Waaga AM, Sayegh MH, Chandraker A. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation. 2002 Apr 27; 73(8):1310-7.
    View in: PubMed
  63. Yamada A, Chandraker A, Laufer TM, Gerth AJ, Sayegh MH, Auchincloss H. Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol. 2001 Nov 15; 167(10):5522-6.
    View in: PubMed
  64. Womer KL, Stone JR, Murphy B, Chandraker A, Sayegh MH. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol. 2001 Nov; 12(11):2500-6.
    View in: PubMed
  65. Azuma H, Takahara S, Matsumoto K, Ichimaru N, Wang JD, Moriyama T, Waaga AM, Kitamura M, Otsuki Y, Okuyama A, Katsuoka Y, Chandraker A, Sayegh MH, Nakamura T. Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol. 2001 Jun; 12(6):1280-92.
    View in: PubMed
  66. Waaga AM, Gasser M, Kist-van Holthe JE, Najafian N, Müller A, Vella JP, Womer KL, Chandraker A, Khoury SJ, Sayegh MH. Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest. 2001 Apr; 107(7):909-16.
    View in: PubMed
  67. Kim KS, Denton MD, Chandraker A, Knoflach A, Milord R, Waaga AM, Turka LA, Russell ME, Peach R, Sayegh MH. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am J Pathol. 2001 Mar; 158(3):977-86.
    View in: PubMed
  68. Tzianabos AO, Chandraker A, Kalka-Moll W, Stingele F, Dong VM, Finberg RW, Peach R, Sayegh MH. Bacterial pathogens induce abscess formation by CD4(+) T-cell activation via the CD28-B7-2 costimulatory pathway. Infect Immun. 2000 Dec; 68(12):6650-5.
    View in: PubMed
  69. Goes N, Chandraker A. Human leukocyte antigen matching in renal transplantation: an update. Curr Opin Nephrol Hypertens. 2000 Nov; 9(6):683-7.
    View in: PubMed
  70. Issazadeh S, Abdallah K, Chitnis T, Chandraker A, Wells AD, Turka LA, Sayegh MH, Khoury SJ. Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. J Clin Invest. 2000 Apr; 105(8):1109-16.
    View in: PubMed
  71. Reynolds J, Tam FW, Chandraker A, Smith J, Karkar AM, Cross J, Peach R, Sayegh MH, Pusey CD. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest. 2000 Mar; 105(5):643-51.
    View in: PubMed
  72. Guttormsen HK, Sharpe AH, Chandraker AK, Brigtsen AK, Sayegh MH, Kasper DL. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect Immun. 1999 Dec; 67(12):6375-84.
    View in: PubMed
  73. Wekerle T, Sayegh MH, Ito H, Hill J, Chandraker A, Pearson DA, Swenson KG, Zhao G, Sykes M. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation. 1999 Nov 15; 68(9):1348-55.
    View in: PubMed
  74. Chandraker A. Diagnostic techniques in the work-up of renal allograft dysfunction--an update. Curr Opin Nephrol Hypertens. 1999 Nov; 8(6):723-8.
    View in: PubMed
  75. Magee CC, Azuma H, Knoflach A, Denton MD, Chandraker A, Iyer S, Buelow R, Sayegh M. In vitro and in vivo immunomodulatory effects of RDP1258, a novel synthetic peptide. J Am Soc Nephrol. 1999 Sep; 10(9):1997-2005.
    View in: PubMed
  76. Mackinnon FG, Ho Y, Blake MS, Michon F, Chandraker A, Sayegh MH, Wetzler LM. The role of B/T costimulatory signals in the immunopotentiating activity of neisserial porin. J Infect Dis. 1999 Sep; 180(3):755-61.
    View in: PubMed
  77. Chandraker A. Ischemia-reperfusion injury in experimental models of organ transplantation. Transplant Proc. 1999 Aug; 31(5):2073.
    View in: PubMed
  78. Onodera K, Chandraker A, Volk HD, Ritter T, Lehmann M, Kato H, Sayegh MH, Kupiec-Weglinski JW. Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2. Transplantation. 1999 Jul 27; 68(2):288-93.
    View in: PubMed
  79. Saborio DV, Chowdhury NC, Jin MX, Chandraker A, Sayegh MH, Oluwole SF. Regulatory T cells maintain peripheral tolerance to islet allografts induced by intrathymic injection of MHC class I allopeptides. Cell Transplant. 1999 Jul-Aug; 8(4):375-81.
    View in: PubMed
  80. Wekerle T, Sayegh MH, Chandraker A, Swenson KG, Zhao Y, Sykes M. Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade. Transplant Proc. 1999 Feb-Mar; 31(1-2):680.
    View in: PubMed
  81. Onodera K, Chandraker A, Kato H, Volk HD, Sayegh MH, Kupiec-Weglinski JW. Distinct tolerance pathways in sensitized rat recipients after blockade of activation signal 1 and signal 2. Transplant Proc. 1999 Feb-Mar; 31(1-2):876-7.
    View in: PubMed
  82. Chowdhury NC, Saborio DV, Garrovillo M, Chandraker A, Magee CC, Waaga AM, Sayegh MH, Jin MX, Oluwole SF. Comparative studies of specific acquired systemic tolerance induced by intrathymic inoculation of a single synthetic Wistar-Furth (RT1U) allo-MHC class I (RT1.AU) peptide or WAG (RT1U)-derived class I peptide. Transplantation. 1998 Oct 27; 66(8):1059-66.
    View in: PubMed
  83. Takada M, Nadeau KC, Hancock WW, Mackenzie HS, Shaw GD, Waaga AM, Chandraker A, Sayegh MH, Tilney NL. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation. 1998 Jun 27; 65(12):1533-42.
    View in: PubMed
  84. Wekerle T, Sayegh MH, Hill J, Zhao Y, Chandraker A, Swenson KG, Zhao G, Sykes M. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med. 1998 Jun 15; 187(12):2037-44.
    View in: PubMed
  85. Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, Sayegh MH. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest. 1998 Jun 1; 101(11):2309-18.
    View in: PubMed
  86. Kato H, Onodera K, Chandraker A, Volk HD, Sayegh MH, Kupiec-Weglinski JW. CD4-targeted therapy and CD28-B7 costimulatory blockage may independently induce tolerance in sensitized allograft recipients. Transplant Proc. 1998 Jun; 30(4):1063-4.
    View in: PubMed
  87. Schaub M, Stadlbauer TH, Chandraker A, Vella JP, Turka LA, Sayegh MH. Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen. J Am Soc Nephrol. 1998 May; 9(5):891-8.
    View in: PubMed
  88. Waaga AM, Chandraker A, Spadafora-Ferreira M, Iyengar AR, Khoury SJ, Carpenter CB, Sayegh MH. Mechanisms of indirect allorecognition: characterization of MHC class II allopeptide-specific T helper cell clones from animals undergoing acute allograft rejection. Transplantation. 1998 Apr 15; 65(7):876-83.
    View in: PubMed
  89. Onodera K, Chandraker A, Korom S, Stadlbauer TH, Kato K, Kasai S, Sayegh MH, Kupiec-Weglinski JW. Agonistic and antagonistic interactions between CTLA4Ig and donor alloantigens in sensitized rat recipients of cardiac allografts. Transplant Proc. 1998 Feb; 30(1):16-8.
    View in: PubMed
  90. Onodera K, Chandraker A, Volk HD, Lehmann M, Korom S, Stadlbauer TH, Kato K, Kasai S, Sayegh MH, Kupiec-Weglinski JW. Role of regulatory T cells in the "infectious" tolerance pathway in transplant recipients. Transplant Proc. 1998 Feb; 30(1):13-5.
    View in: PubMed
  91. Chandraker A, Takada M, Nadeau KC, Peach R, Tilney NL, Sayegh MH. CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Kidney Int. 1997 Dec; 52(6):1678-84.
    View in: PubMed
  92. Gallon L, Chandraker A, Issazadeh S, Peach R, Linsley PS, Turka LA, Sayegh MH, Khoury SJ. Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model. J Immunol. 1997 Nov 1; 159(9):4212-6.
    View in: PubMed
  93. Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest. 1997 Sep 1; 100(5):1199-203.
    View in: PubMed
  94. Onodera K, Chandraker A, Schaub M, Stadlbauer TH, Korom S, Peach R, Linsley PS, Sayegh MH, Kupiec-Weglinski JW. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses. J Immunol. 1997 Aug 15; 159(4):1711-7.
    View in: PubMed
  95. Korom S, De Meester I, Stadlbauer TH, Chandraker A, Schaub M, Sayegh MH, Belyaev A, Haemers A, Scharpé S, Kupiec-Weglinski JW. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation. 1997 May 27; 63(10):1495-500.
    View in: PubMed
  96. Chandraker A, Russell ME, Glysing-Jensen T, Willett TA, Sayegh MH. T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen. Transplantation. 1997 Apr 27; 63(8):1053-8.
    View in: PubMed
  97. Akalin E, Chandraker A, Sayegh M, Turka LA. Role of the CD28:B7 costimulatory interaction in alloimmune responses. Kidney Int Suppl. 1997 Mar; 58:S8-10.
    View in: PubMed
  98. Nadeau K, Azuma H, Chandraker A, Sayegh MH, Tilney NL. Inhibition of CD28-B7 T-cell costimulatory activation pathway affects intragraft cytokine and growth factor expression in chronic renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):1038.
    View in: PubMed
  99. Onodera K, Hancock WW, Graser E, Volk HD, Lehmann M, Chandraker A, Sayegh MH, Kupiec-Weglinski JW. Th2-type cytokines in the "infectious" tolerance pathway. Transplant Proc. 1997 Feb-Mar; 29(1-2):1290-1.
    View in: PubMed
  100. Knoflach A, Chandraker A, Sayegh MH. Chronic rejection from bedside to bench: role of T cells. Ann Transplant. 1997; 2(2):53-60.
    View in: PubMed
  101. Akalin E, Chandraker A, Russell ME, Turka LA, Hancock WW, Sayegh MH. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo. Transplantation. 1996 Dec 27; 62(12):1942-5.
    View in: PubMed
  102. Azuma H, Chandraker A, Nadeau K, Hancock WW, Carpenter CB, Tilney NL, Sayegh MH. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A. 1996 Oct 29; 93(22):12439-44.
    View in: PubMed
  103. Khoury SJ, Gallon L, Verburg RR, Chandraker A, Peach R, Linsley PS, Turka LA, Hancock WW, Sayegh MH. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol. 1996 Oct 15; 157(8):3700-5.
    View in: PubMed
  104. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, Hancock WW. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol. 1995 Nov 15; 155(10):4521-4.
    View in: PubMed
  105. Renwick DS, Chandraker A, Bannister P. Missed neuroleptic malignant syndrome. BMJ. 1992 Mar 28; 304(6830):831-2.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Chandraker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (423) concept(s)
_
Co-Authors
See all (57) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_